Drug-induced hepatitis: histologic clues to a difficult diagnosis. Issue 12 (December 2017)

• Record Type: Journal Article
• Authors: Bhaijee, Feriyl; Anders, Robert A.
• Is Part Of: Diagnostic histopathology. Volume 23:Issue 12(2017)
• Page Start: 559
• Page End: 562
• Publication Date: 2017-12
• Subjects: DILI -- drug injury -- drug-induced -- hepatitis -- Kupffer cell -- statin; Histology, Pathological -- Periodicals; Cytodiagnosis -- Periodicals; Diagnosis, Laboratory -- Periodicals; Pathology -- Periodicals; Histopathologie -- Périodiques; Pathologie -- Périodiques; Cytodiagnostics -- Périodiques; Diagnostics biologiques -- Périodiques; Histologie -- Technique -- Périodiques; Electronic journals; 616.07582
• DOI: 10.1016/j.mpdhp.2017.11.003
• Languages: English
• ISSNs: 1756-2317

Abstract

Abstract: Drug-induced liver injury (DILI) results from two chief mechanisms of action: idiosyncratic hepatotoxicity, which typically manifests with prominent inflammation, and intrinsic hepatotoxicity, which demonstrates necrosis with negligible inflammation. Clinically, DILI is classified into hepatitic, cholestatic, or mixed presentations based on the pattern of liver enzyme elevation. As many etiologic factors can result in abnormal liver enzymes, the clinical clue to diagnosing DILI is symptomatic and biochemical improvement upon withdrawal of the offending agent. Histologically, DILI manifests in four main patterns of injury: i) inflammation-predominant acute hepatitis, ii) necrosis-predominant acute hepatitis, iii) resolving hepatitis, and iv) syncytial giant cell hepatitis. In contrast to the characteristic features of both acute hepatitis and syncytial giant cell hepatitis, resolving drug-induced hepatitis lacks specific histologic features and may mimic other mild forms of chronic hepatitis. Ultimately, the presence of sinusoidal PASD + Kupffer cell aggregates – in the absence of significant hepatocellular inflammation or injury – is the histologic hallmark of resolving drug-induced hepatitis.